NCT02350218 (PROVISION) is a Phase 2 clinical trial of Eglandin in Evidence of Liver Transplantation, sponsored by Asan Medical Center.

Who is sponsoring NCT02350218?

NCT02350218 is sponsored by Asan Medical Center.

What drugs are being tested in NCT02350218?

Interventions in NCT02350218: Eglandin.

What condition does NCT02350218 study?

NCT02350218 studies Evidence of Liver Transplantation.

Is NCT02350218 still recruiting?

NCT02350218 is currently status unknown. Last updated 5 July 2018.

Last reviewed 2018-07-05 · How we verify

NCT02350218: PROVISION

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open-label, Single Center, Randomized Clinical Trial to Evaluate Safety, Efficacy of Eglandin® (Alprostadil) 360㎍, 720㎍ in Living Donor Liver Transplanted Patient

Status unknown Phase 2 Last updated 5 July 2018

What this trial tests

Phase 2 trial testing Eglandin in Evidence of Liver Transplantation in 76 participants. Status unknown.

Timeline

1 March 2015

Primary endpoint
1 December 2018

1 December 2018

Quick facts

Lead sponsor	Asan Medical Center
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	76
Start date	1 March 2015
Primary completion	1 December 2018
Estimated completion	1 December 2018
Sites	1 location across South Korea

Drugs / interventions tested

Eglandin — full drug profile →

Conditions studied

Evidence of Liver Transplantation — all drugs for Evidence of Liver Transplantation →

Sponsor

Asan Medical Center

Who can join

Adults 19 to 65, any sex, with Evidence of Liver Transplantation. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Peak AST level within 7 days of Eglandin administration
Time frame: 7 days

Sponsor's own description

The purpose of this study is to evaluate superiority of Eglandin® (Alprostadil) 720㎍compared to 360㎍ in terms of safety, efficacy in living donor liver transplant patient, peak AST levels followed by Eglandin administration were assessed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Asan Medical Center trials

Trials by the same sponsor.

NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02350218 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
Last refreshed: 5 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02350218.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing